Cadrenal Therapeutics, Inc. (CVKD) News
Follow Cadrenal Therapeutics, Inc. (CVKD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CVKD - Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
CVKD - Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
NEWS | Sep 21, 2026, 08:30 PM UTC
L
Cadrenal Therapeutics CEO Quang X. Pham to participate in H.C. Wainwright conference
Cadrenal Therapeutics said CEO Quang X. Pham will participate in H.C. Wainwright's 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
CVKD - Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
CVKD - Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
EQUITY | Sep 03, 2026, 12:02 PM UTC
L
Cadrenal Therapeutics (CVKD) reports Q2 2026 financial results
Cadrenal Therapeutics reports its second quarter 2026 financial results and provides a corporate update on its Cardiac Acute Critical Care franchise and strategic partnering process.
EARNINGS | Aug 13, 2026, 08:15 PM UTC
H
Cadrenal Therapeutics Expands CAD-1005 Strategy
Cadrenal Therapeutics expands cardiac acute care strategy
EQUITY | Aug 03, 2026, 12:31 PM UTC
L
Reported Earlier, Cadrenal Therapeutics Announces Up To $8.8M Private Placement Of 960,000 Shares At $3.125 Per Share, Priced At-The-Market
Reported Earlier, Cadrenal Therapeutics Announces Up To $8.8M Private Placement Of 960,000 Shares At $3.125 Per Share, Priced At-The-Market
EQUITY | Jul 01, 2026, 07:46 AM UTC